$PCT
PureCycle Technologies, Inc. Stock $pct

$pct Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000183003323000036 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$13.62M	$12.94M
YoY Change	5.13%	-12.29%
% of Gross Profit
Research & Development	$160.0K	$393.0K
YoY Change	-36.0%	15.93%
% of Gross Profit
Depreciation & Amortization	$4.000M	$1.300M
YoY Change	344.44%	58.92%
% of Gross Profit
Operating Expenses	$27.80M	$21.82M
YoY Change	41.46%	14.04%
Operating Profit
YoY Change
Interest Expense	-$2.449M	$1.276M
YoY Change	-1491.48%	187.39%
% of Operating Profit
Other Income/Expense, Net	-$28.78M	-$4.021M
YoY Change	-718.95%	-36.15%
Pretax Income	-$56.58M	-$25.84M
YoY Change	277.07%	1.61%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$56.58M	-$25.84M
YoY Change	277.07%	1.61%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.35	-$0.16
Diluted Earnings Per Share	-$0.35	-$0.16
COMMON SHARES
Basic Shares Outstanding	163.7M shares	163.7M shares
Diluted Shares Outstanding	163.7M shares	163.6M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.89M	$38.38M
YoY Change	-91.74%	-90.82%
Cash & Equivalents	$28.89M	$38.38M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$46.97M	$75.40M
YoY Change	-40.59%	-27.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$75.85M	$113.8M
YoY Change	-82.31%	-78.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$628.8M	$579.6M
YoY Change	81.95%	117.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$158.5M	$163.1M
YoY Change	58.14%	67.84%
Total Long-Term Assets	$817.2M	$761.6M
YoY Change	78.56%	101.79%
TOTAL ASSETS
Total Short-Term Assets	$75.85M	$113.8M
Total Long-Term Assets	$817.2M	$761.6M
Total Assets	$893.0M	$875.4M
YoY Change	0.73%	-2.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.86M	$22.58M
YoY Change	111.88%	1126.34%
Accrued Expenses	$35.32M	$41.90M
YoY Change	32.16%	116.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.426M
YoY Change
Total Short-Term Liabilities	$54.36M	$70.61M
YoY Change	62.81%	158.65%
LONG-TERM LIABILITIES
Long-Term Debt	$283.8M	$233.8M
YoY Change	21.81%	0.44%
Other Long-Term Liabilities	$1.221M	$1.236M
YoY Change	8.82%	11.75%
Total Long-Term Liabilities	$1.221M	$235.0M
YoY Change	8.82%	21149.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$54.36M	$70.61M
Total Long-Term Liabilities	$1.221M	$235.0M
Total Liabilities	$458.8M	$387.9M
YoY Change	36.73%	15.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$324.9M	-$268.4M
YoY Change	63.93%	46.49%
Common Stock	$164.0K	$164.0K
YoY Change	0.61%	0.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$434.2M	$487.6M
YoY Change
Total Liabilities & Shareholders Equity	$893.0M	$875.4M
YoY Change	0.73%	-2.6%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$56.58M	-$25.84M
YoY Change	277.07%	1.61%
Depreciation, Depletion And Amortization	$4.000M	$1.300M
YoY Change	344.44%	58.92%
Cash From Operating Activities	-$25.67M	-$14.76M
YoY Change	41.3%	-12.82%
INVESTING ACTIVITIES
Capital Expenditures	$77.61M	$46.63M
YoY Change	-203.63%	-189.37%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$99.37M
YoY Change	-100.0%	-287.91%
Cash From Investing Activities	-$77.61M	$52.74M
YoY Change	-10.59%	-150.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	55.73M	-$1.632M
YoY Change	-185863.33%	-100.66%
NET CHANGE
Cash From Operating Activities	-25.67M	-$14.76M
Cash From Investing Activities	-77.61M	$52.74M
Cash From Financing Activities	55.73M	-$1.632M
Net Change In Cash	-47.55M	$36.35M
YoY Change	-54.71%	-71.19%
FREE CASH FLOW
Cash From Operating Activities	-$25.67M	-$14.76M
Capital Expenditures	$77.61M	$46.63M
Free Cash Flow	-$103.3M	-$61.39M
YoY Change	-282.07%	-274.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001830033
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period Business Days Prior To Notice Of Redemption DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodBusinessDaysPriorToNoticeOfRedemption	P3D
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40234
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	PureCycle Technologies, Inc.
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2293091
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5950 Hazeltine National Drive,
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32822
CY2023Q1	dei	City Area Code CityAreaCode	877
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	648-3565
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	163670396	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38381000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63892000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	98592000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	68028000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	68850000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7375000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4883000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	113784000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	236217000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	157466000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	94781000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	5657000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	5483000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18939000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19136000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	579585000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	505719000	usd
CY2023Q1	us-gaap	Assets Assets	875431000	usd
CY2022Q4	us-gaap	Assets Assets	861336000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	22577000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1667000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41902000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35102000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	6127000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1532000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	70606000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38301000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5000000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5000000	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	233778000	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	233513000	usd
CY2023Q1	pct	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	60718000	usd
CY2022Q4	pct	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	55883000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16522000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16620000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1236000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1136000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	387860000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	350453000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	163671000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	163671000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	163550000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	163550000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	164000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	164000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	755774000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	753885000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-641000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268367000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242525000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	487571000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	510883000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	875431000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	861336000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	8493000	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	4048000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	393000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	339000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12935000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14747000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	21821000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	19134000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1276000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-444000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4835000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5835000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-462000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4021000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6298000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25842000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25432000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	163588000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	163588000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133244000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133244000	shares
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	641000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-340000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25201000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25772000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	510883000	usd
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	277000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2166000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	641000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25842000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	487571000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	381535000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	205296000	usd
CY2022Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1049000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3171000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-340000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25432000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	563181000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25842000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25432000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2166000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3171000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4835000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5835000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1294000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	818000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	265000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	244000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	138000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-146000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	926000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	287000	usd
CY2023Q1	pct	Increase Decrease In Prepaid Expenses And Other Assets Current IncreaseDecreaseInPrepaidExpensesAndOtherAssetsCurrent	1148000	usd
CY2022Q1	pct	Increase Decrease In Prepaid Expenses And Other Assets Current IncreaseDecreaseInPrepaidExpensesAndOtherAssetsCurrent	479000	usd
CY2023Q1	pct	Increase Decrease In Prepaid Expenses And Other Assets Noncurrent IncreaseDecreaseInPrepaidExpensesAndOtherAssetsNoncurrent	174000	usd
CY2022Q1	pct	Increase Decrease In Prepaid Expenses And Other Assets Noncurrent IncreaseDecreaseInPrepaidExpensesAndOtherAssetsNoncurrent	-11000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1218000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	747000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2116000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2503000	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	324000	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	324000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-597000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-93000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14755000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16924000	usd
CY2023Q1	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	46632000	usd
CY2022Q1	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	52177000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	98070000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	99371000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	45189000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	52739000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-105058000	usd
CY2023Q1	pct	Payments Of Notes Issuance Costs PaymentsOfNotesIssuanceCosts	1344000	usd
CY2022Q1	pct	Payments Of Notes Issuance Costs PaymentsOfNotesIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	277000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1049000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-11000	usd
CY2022Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-10000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	206071000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	43929000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	775000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1632000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	248166000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36352000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	126184000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227523000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	263858000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	263875000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	390042000	usd
CY2023Q1	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	30809000	usd
CY2022Q1	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	13918000	usd
CY2023Q1	pct	Construction In Progress Expenditures Accrued For But Not Yet Paid ConstructionInProgressExpendituresAccruedForButNotYetPaid	20509000	usd
CY2022Q1	pct	Construction In Progress Expenditures Accrued For But Not Yet Paid ConstructionInProgressExpendituresAccruedForButNotYetPaid	329000	usd
CY2023Q1	pct	Construction In Progress Expenditures Owed But Not Yet Paid ConstructionInProgressExpendituresOwedButNotYetPaid	4271000	usd
CY2022Q1	pct	Construction In Progress Expenditures Owed But Not Yet Paid ConstructionInProgressExpendituresOwedButNotYetPaid	4271000	usd
CY2021Q1	pct	Business Combination Contingent Consideration Liability Shares Maximum Issued BusinessCombinationContingentConsiderationLiabilitySharesMaximumIssued	4000000	shares
CY2021Q1	pct	Business Combination Contingent Consideration Liability Shares BusinessCombinationContingentConsiderationLiabilityShares	2000000	shares
CY2021Q1	pct	Business Combination Contingent Consideration Liability Earnout Period BusinessCombinationContingentConsiderationLiabilityEarnoutPeriod	P1Y
CY2021Q1	pct	Business Combination Contingent Consideration Liability Earnout Period Stock Price Trigger BusinessCombinationContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger	18.00
CY2021Q1	pct	Business Combination Contingent Consideration Liability Earnout Period Threshold Trading Days BusinessCombinationContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays	20	tradingday
CY2021Q1	pct	Business Combination Contingent Consideration Liability Earnout Period Threshold Trading Day Period BusinessCombinationContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDayPeriod	30	tradingday
CY2021Q1	pct	Business Combination Contingent Consideration Liability Shares BusinessCombinationContingentConsiderationLiabilityShares	2000000	shares
CY2022Q1	pct	Business Combination Acquisition Related Costs Advisory Legal And Accounting BusinessCombinationAcquisitionRelatedCostsAdvisoryLegalAndAccounting	800000	usd
CY2023Q1	pct	Working Capital WorkingCapital	43178000	usd
CY2022Q4	pct	Working Capital WorkingCapital	197916000	usd
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	163670000	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38381000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63892000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	98592000	usd
CY2023Q1	pct	Unrestricted Liquidity Amount UnrestrictedLiquidityAmount	38381000	usd
CY2022Q4	pct	Unrestricted Liquidity Amount UnrestrictedLiquidityAmount	162484000	usd
CY2023Q1	pct	Expected Investment To Complete Facility Current Fiscal Year Amount Set Aside In Restricted Cash ExpectedInvestmentToCompleteFacilityCurrentFiscalYearAmountSetAsideInRestrictedCash	0	usd
CY2022Q4	pct	Expected Investment To Complete Facility Current Fiscal Year Amount Set Aside In Restricted Cash ExpectedInvestmentToCompleteFacilityCurrentFiscalYearAmountSetAsideInRestrictedCash	54560000	usd
CY2023Q1	pct	Available Unrestricted Liquidity Amount AvailableUnrestrictedLiquidityAmount	38381000	usd
CY2022Q4	pct	Available Unrestricted Liquidity Amount AvailableUnrestrictedLiquidityAmount	107924000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	225494000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	163631000	usd
CY2023Q1	pct	Common Stock Number Of Votes For Each Share Held CommonStockNumberOfVotesForEachShareHeld	1	vote
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268367000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242525000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25842000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25432000	usd
CY2023Q1	pct	Available Unrestricted Liquidity Amount AvailableUnrestrictedLiquidityAmount	38400000	usd
CY2023Q1	pct	Loan Agreement Limited Waiver Terms Additional Capitalized Interest Agreed To Fund LoanAgreementLimitedWaiverTermsAdditionalCapitalizedInterestAgreedToFund	12300000	usd
CY2023Q1	pct	Loan Agreement Limited Waiver Net Amount Contribute For Construction Project LoanAgreementLimitedWaiverNetAmountContributeForConstructionProject	25200000	usd
CY2023Q1	pct	Loan Agreement Limited Waiver Amount Transfer To Escrow Amount LoanAgreementLimitedWaiverAmountTransferToEscrowAmount	50000000	usd
CY2023Q1	pct	Loan Agreement Limited Waiver Terms Amount Agreed To Release From Trustee Account LoanAgreementLimitedWaiverTermsAmountAgreedToReleaseFromTrusteeAccount	13200000	usd
CY2023Q1	pct	Cash And Cash Equivalents Amount Transfer Of Cash From Unrestricted To Restricted Cash CashAndCashEquivalentsAmountTransferOfCashFromUnrestrictedToRestrictedCash	74300000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	249550000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	249550000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	15772000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	16037000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	233778000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	233513000	usd
CY2020Q4	pct	Feedstock Supply Agreement Number Of Suppliers FeedstockSupplyAgreementNumberOfSuppliers	1	supplier
CY2020Q4	pct	Feedstock Supply Agreement Number Of Purchasers FeedstockSupplyAgreementNumberOfPurchasers	2000	purchaser
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	163670000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	163550000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	163550000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	613000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28900
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M12D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	613000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28900
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	613000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28900
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	459000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5720
CY2023Q1	pct	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P10Y
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1072000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18980
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	613000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.07
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	11.50
CY2021Q1	pct	Class Of Warrant Or Right Redemption Price Of Warrants Or Rights ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights	0.01
CY2021Q1	pct	Class Of Warrant Or Right Redemption Of Warrants Or Rights Written Notice Of Redemption Threshold ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsWrittenNoticeOfRedemptionThreshold	P30D
CY2021Q1	pct	Business Combination Contingent Consideration Liability Earnout Period Stock Price Trigger BusinessCombinationContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger	18.00
CY2021Q1	pct	Business Combination Contingent Consideration Liability Earnout Period Threshold Trading Days BusinessCombinationContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays	20	tradingday
CY2021Q1	pct	Business Combination Contingent Consideration Liability Earnout Period Threshold Trading Day Period BusinessCombinationContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDayPeriod	30	tradingday
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25842000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25842000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25432000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25432000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	163588000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	163588000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133244000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133244000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	589463000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9878000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	579585000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	514317000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8598000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	505719000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1300000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	800000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	99234000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	642000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	98592000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	92253000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	91669000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis	6981000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	6923000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	99234000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	98592000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2021Q2	pct	Loss Contingency Number Of Class Actions LossContingencyNumberOfClassActions	2	classaction
CY2022Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P15Y
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	52300000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P30Y
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27700000	eur

Files In Submission

Name	View Source	Status
pct-20230331_def.xml	Edgar Link	unprocessable
pct-20230331_cal.xml	Edgar Link	unprocessable
0001830033-23-000036-index-headers.html	Edgar Link	pending
0001830033-23-000036-index.html	Edgar Link	pending
0001830033-23-000036.txt	Edgar Link	pending
0001830033-23-000036-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pct-20230331.htm	Edgar Link	pending
pct-20230331.xsd	Edgar Link	pending
pct-20230331_g1.jpg	Edgar Link	pending
pct-form10xqex311q12023.htm	Edgar Link	pending
pct-form10xqex312q12023.htm	Edgar Link	pending
pct-form10xqex321q12023.htm	Edgar Link	pending
pct-form10xqex322q12023.htm	Edgar Link	pending
pct-form10xqq12023ex103pgx.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pct-20230331_lab.xml	Edgar Link	unprocessable
pct-20230331_pre.xml	Edgar Link	unprocessable
pct-20230331_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCT
PureCycle Technologies, Inc. Stock $pct

2023 Q2 Form 10-Q Financial Statement

#000183003323000036 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCT PureCycle Technologies, Inc. Stock $pct

2023 Q2 Form 10-Q Financial Statement

#000183003323000036 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCT
PureCycle Technologies, Inc. Stock $pct